Clearmind Medicine Receives Final Approval to Expand its FDA Regulated Phase 1/2a Clinical Trial for Alcohol Use Disorder at Hadassah Medical Center

Core Viewpoint - Clearmind Medicine Inc. has received final approval for its Phase 1/2a clinical trial of CMND-100, a drug candidate for treating Alcohol Use Disorder (AUD), from Hadassah Medical Center in Israel, marking a significant step in addressing AUD, which is responsible for 4.7% of global deaths [1][3]. Group 1: Clinical Trial Details - The clinical trial will involve prestigious institutions such as Yale School of Medicine, Johns Hopkins University, and Tel Aviv Sourasky Medical Center, with leadership from Prof. Joseph Caraco at Hadassah [2]. - The trial aims to assess the safety, tolerability, and pharmacokinetic profile of CMND-100, while also evaluating its preliminary efficacy in reducing alcohol cravings and consumption among AUD patients [3]. Group 2: Company Overview - Clearmind is focused on developing novel psychedelic-derived therapeutics to address significant health issues, including AUD, with the goal of commercializing these compounds as regulated medicines, foods, or supplements [4]. - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [5].